Oncolytics Biotech® Engages Experts on Pancreatic Cancer Research
Oncolytics Biotech® Engages Experts on Pancreatic Cancer Research
Oncolytics Biotech Inc. (NASDAQ: ONCY) is set to host an important key opinion leader (KOL) webinar focused on advancements in treatments for pancreatic and gastrointestinal cancers. This event will bring together leading experts in the field to discuss the promising immunotherapy agent, pelareorep, used in the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
Insightful KOL Webinar Information
The webinar highlights a discussion scheduled for July 22, 2025, at 1:00 p.m. ET, fostering a collaborative environment where expertise meets innovation. Attendees can expect key insights from notable KOLs, including Dirk Arnold, M.D., Ph.D., Alexander Eggermont, M.D., Ph.D., Sanjay Goel, M.D., M.S., FASCO, and Devalingam Mahalingam, M.D., Ph.D. These experts will delve into pelareorep's existing clinical data and its potential as a leading immunotherapeutic option in specific cancer types.
Joining Forces with Expert Voices
Panelists will comprise KOLs representing prestigious institutions, including Asklepios Tumorzentrum Hamburg and the Rutgers Cancer Institute of New Jersey. Their backgrounds range from research in immunotherapy to innovations in drug development, ensuring a session rich in knowledge. The discussion will be complemented by a Q&A session, allowing participants to engage directly with the experts and gain an in-depth understanding of the evolving landscape of cancer treatment.
Meet the Experts
Dr. Dirk Arnold
Dr. Dirk Arnold is a renowned expert and Director of Asklepios Tumorzentrum Hamburg. With a robust research focus on gastrointestinal cancers and immunotherapy, he has significantly contributed to clinical trials like the GOBLET trial. His academic journey spans reputable institutions where he earned his medical degree and later specialized in oncology.
Dr. Alexander Eggermont
Another prominent figure, Dr. Alexander Eggermont, serves as a Professor of Clinical & Translational Immunotherapy. His illustrious career includes leadership roles at Gustave Roussy Cancer Campus in France and comprehensive research contributions, which have gained international recognition through numerous peer-reviewed publications.
The Role of Pelareorep in Cancer Treatment
Pelareorep, an intravenously delivered immunotherapeutic agent, has shown encouraging results in clinical studies for metastatic breast cancer and pancreatic cancer. Oncolytics has focused much of its research on how pelareorep restructures the immune response to target cancerous cells effectively, altering the tumor microenvironment from “cold” to “hot.” This modification prompts a more robust immune attack against tumors, enhancing overall treatment efficacy.
Combination Trials Underway
As part of its commitment to developing effective cancer treatments, Oncolytics is continuously conducting and planning clinical trials combining pelareorep with other approved oncology therapies. This strategy has the potential to pave the way for innovative solutions for patients battling metastatic conditions.
About Oncolytics Biotech Inc.
Founded with the vision of advancing cancer immunotherapy, Oncolytics is at the forefront of biopharmaceutical innovation. The company’s pipeline highlights pelareorep’s capabilities across several malignancies, leading to their entry into registrational studies under the FDA's Fast Track designation. As it empowers scientists and clinicians to understand and combat cancer more effectively, the impact of Oncolytics Biotech extends far beyond mere numbers.
Frequently Asked Questions
What is the focus of the Oncolytics KOL webinar?
The webinar will focus on the use of pelareorep in treating pancreatic and gastrointestinal cancers, featuring discussions with leading medical experts.
Who are the KOLs participating in the webinar?
Participating KOLs include Dr. Dirk Arnold, Dr. Alexander Eggermont, Dr. Sanjay Goel, and Dr. Devalingam Mahalingam, all experts in oncology and immunotherapy.
What is pelareorep?
Pelareorep is an immunotherapeutic agent developed by Oncolytics Biotech, aimed at enhancing anti-cancer immune responses and used in treating various solid tumors.
How can one participate in the webinar?
Interested individuals can register for the webinar to gain insights into the latest advancements in cancer treatment.
What is the significance of the clinical trials mentioned?
These trials are essential for validating the effectiveness of pelareorep and exploring its potential when combined with other therapeutic agents in treating challenging cancers.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
